Open Access

Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide‑induced disseminated intravascular coagulation in rats

  • Authors:
    • Yukio Suga
    • Fumio Akita
    • Shinya Yamada
    • Eriko Morishita
    • Hidesaku Asakura
  • View Affiliations

  • Published online on: November 22, 2021     https://doi.org/10.3892/br.2021.1488
  • Article Number: 5
  • Copyright: © Suga et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to clarify the effect of recombinant human erythropoietin (EPO) and low molecular weight heparin (LMWH) on a rat model of lipopolysaccharide (LPS)‑induced disseminated intravascular coagulation (DIC). Experimental DIC was induced by sustained infusion of 5 mg/kg LPS for 4 h. EPO or LMWH was then administered to the LPS‑induced DIC model. LPS‑induced consumption coagulopathy, hemostatic activation and plasma TNF elevation remained unaltered in the LPS+EPO group, except for the D‑dimer levels, and these abnormalities were significantly improved in the LPS+LMWH group. Plasma alanine aminotransferase (ALT) levels were markedly reduced in the LPS+EPO group, accompanied by a significant suppression of hepatocellular apoptosis. In the LPS+LMWH group, plasma creatinine levels and glomerular fibrin deposition were significantly attenuated, along with plasma ALT levels and hepatocellular apoptosis. Thus, a single administration of EPO may improve hepatic dysfunction by primarily exerting an anti‑apoptotic, not anticoagulant, effect in the LPS‑induced DIC model.

Related Articles

Journal Cover

January-2022
Volume 16 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Suga Y, Akita F, Yamada S, Morishita E and Asakura H: Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide‑induced disseminated intravascular coagulation in rats. Biomed Rep 16: 5, 2022
APA
Suga, Y., Akita, F., Yamada, S., Morishita, E., & Asakura, H. (2022). Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide‑induced disseminated intravascular coagulation in rats. Biomedical Reports, 16, 5. https://doi.org/10.3892/br.2021.1488
MLA
Suga, Y., Akita, F., Yamada, S., Morishita, E., Asakura, H."Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide‑induced disseminated intravascular coagulation in rats". Biomedical Reports 16.1 (2022): 5.
Chicago
Suga, Y., Akita, F., Yamada, S., Morishita, E., Asakura, H."Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide‑induced disseminated intravascular coagulation in rats". Biomedical Reports 16, no. 1 (2022): 5. https://doi.org/10.3892/br.2021.1488